Skip to main content
OpenTrials
Completed

NCT Number: NCT06764862

Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis

This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with Idiopathic Pulmonary Fibrosis (IPF) prior to screening, patients must meet both of the following criteria:
  • IPF based on 2022 ATS/ERS/JRS/ALAT Guideline as confirmed by the investigator based on chest HRCT scan taken before or during screening period and if available surgical lung biopsy.
  • Usual interstitial pneumonia (UIP) or probable UIP HRCT pattern consistent with the clinical diagnosis of IPF, as confirmed by the investigator prior to screening. if indeterminate HRCT finding IPF may be confirmed locally by (historical) biopsy.
  • Percentage Predicted Forced Vital Capacity (ppFVC) ≥45% at screening period. 3. Diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for haemoglobin [Hb]) ≥ 25% of predicted normal at screening period.
  • Patients have to be either:
  • not on therapy with nintedanib or pirfenidone for at least 8 weeks prior to screening and during the screening period, and not planning to start or restart anti fibrotic therapy.
  • on stable therapy with nintedanib or pirfenidone for at least 8 weeks prior to screening and during the screening period.

Exclusion criteria

  • Clinically significant airways obstruction (Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC) < 0.7) at screening.
  • In the opinion of the Investigator, other clinically significant pulmonary abnormalities.
  • Acute IPF exacerbation within 4 months prior to screening and/or during the screening period (investigator-determined).
  • Lower respiratory tract infection requiring antibiotics within 2 weeks prior to screening and/or during the screening period.
  • Major surgery (major according to the investigator's assessment) performed within 3 months prior to screening or planned during the course of the trial. (Being on a transplant list is allowed).
  • History of malignancy within 5 years prior to screening.
  • Any suicidal behavior within 2 years prior to screening (i.e. actual attempts, interrupted attempts, abandoned attempts, or prepared actions or attitudes).

Treatment and study plan

HSK44459 dose 1

Drug

HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

HSK44459 dose 2

Drug

HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

HSK44459 dose 3

Drug

HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

Placebo

Drug

Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

Primary outcomes

  1. The change from baseline in forced vital capacity (FVC) at week 12

    Time frame: day 1 and week 12

    FVC is a standard pulmonary function test used to quantify respiratory muscle weakness

Secondary outcomes

  1. Relative change from baseline in FVC at week 12

    Time frame: day 1 and week 12

    FVC is a standard pulmonary function test used to quantify respiratory muscle weakness

  2. The change from baseline in percentage predicted forced vital capacity ( ppFVC) at week 12

    Time frame: day 1 and week 12

    FVC is a standard pulmonary function test used to quantify respiratory muscle weakness

Sponsors and collaborators

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd.

Industry

Registry information

Official study title

A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Idiopathic Pulmonary Fibrosis

Acronym: IPF

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 9, 2025
Registry last updated
Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.